LINK MT MEDICAL GUIDE
Japan Medical 90-Day Tracker
Beyond daily 24–72 hour updates, LINK MT tracks important projects across the full lifecycle: review/approval → reimbursement → launch → hospital use → international-patient access.
| Priority item | Current stage | What we track |
|---|---|---|
| Oveporexton (Orzeyful) | Approved | Adult narcolepsy type 1; continue tracking reimbursement, launch and hospital availability. |
| Bepirovirsen | Approved | Functional cure indication for persistent hepatitis B virus infection; monitor safety management and hospital use. |
| KEYJECT | Approved | Subcutaneous pembrolizumab combination; monitor implementation versus IV treatment. |
| RiHEART iPS cardiomyocyte sheet | Conditional/time-limited approval + insured use | Severe heart failure; follow treated cases, all-case surveillance and long-term outcomes. |
| Signatera MRD | Approved diagnostic | Track indication, patient selection and how results affect treatment decisions. |
| Generative-AI SaMD review points | Regulatory draft | Track Japanese rules for approval, accountability and model updates. |
| CiRA SOD1 ALS editing | Basic research | iPS-cell stage; clearly separate from clinical trials or patient recruitment. |
| UTokyo light-controlled mRNA delivery | Preclinical | Cell and mouse stage; track progression toward human studies. |
| JASMINE canine MVR | Clinical service | Track overseas pathway and compare with local Korean KASMINE options. |
| UTokyo/NVLU veterinary trials | Clinical research | Track PD-1, organoids, MUO MSC and HCM by recruitment and eligibility. |
三つの長期事業方向
Precision Checkups & Ongoing Health Management
A structured pathway for precision checkups in Japan, cancer screening, follow-up testing, specialist referral and ongoing health management.
→Immune Cell & Advanced Medicine
Immune cell therapy, regenerative medicine, precision medicine, new drugs and clinical trials, separated by approval status and clinical evidence.
→Integrated Health & Medical Aesthetics
Self-pay wellness and aesthetic services are reviewed for safety, indications, evidence level and realistic outcomes.
→Veterinary Medicine
JASMINE, UTokyo VMC and NVLU projects are tracked separately by evidence, eligibility and cross-border value.
→Each item is presented with its evidence level, indication and regulatory status clearly separated.